Actively Recruiting
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Led by Hebei Medical University Fourth Hospital · Updated on 2025-06-26
30
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of Borderline Resectable/locally advanced pancreatic cancer.
CONDITIONS
Official Title
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years old, male or female
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Tumor located in the pancreas
- Pathological diagnosis of pancreatic ductal adenocarcinoma or acinar cell carcinoma
- No distant metastasis present
- Pancreatic tumor located more than 1 cm from the duodenum
- Clinical assessment indicates locally advanced or borderline resectable pancreatic cancer
- No history of immune system diseases, other cancers, myocarditis, coronary heart disease, cardiovascular or cerebrovascular diseases, thyroid dysfunction, liver or kidney diseases, psychiatric or infectious diseases, or systemic diseases other than those mentioned
- Willing to participate, able to adhere to study procedures, and provide written informed consent
You will not qualify if you...
- Does not meet the above inclusion criteria
- Poor cognitive ability or mental disorders preventing answering questions or completing questionnaires
- Considered inappropriate for the study by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050011
Actively Recruiting
Research Team
L
Li Peng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here